{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:49:29Z","timestamp":1789555769870,"version":"build-2803163510"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"DOI":"10.7759\/cureus.50407","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T21:49:06Z","timestamp":1702417746000},"source":"Crossref","is-referenced-by-count":1,"title":["Disseminated Mycobacterium bovis Infection: A Rare Complication of Bacillus Calmette-Gu\u00e9rin Immunotherapy"],"prefix":"10.7759","author":[{"given":"Marina","family":"Henriques Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrine","family":"Dahlstedt Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurdes","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Safety and efficacy of various strains of bacille Calmette-Gu\u00e9rin in the treatment of bladder tumours in standard clinical practice","volume":"42","author":"Unda-Urzaiz M","year":"2018","unstructured":"Unda-Urzaiz M, Cozar-Olmos JM, Mi\u00f1ana-Lopez B, et al.. Safety and efficacy of various strains of bacille Calmette-Gu\u00e9rin in the treatment of bladder tumours in standard clinical practice. Actas Urol Esp (Engl Ed). 2018, 42:238-48. 10.1016\/j.acuro.2017.10.003","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han RF","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006, 67:1216-23. 10.1016\/j.urology.2005.12.014","journal-title":"Urology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley MD","year":"2010","unstructured":"Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010, 36:195-205. 10.1016\/j.ctrv.2009.12.005","journal-title":"Cancer Treat Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm DL","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, et al.. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000, 163:1124-9. 10.1016\/S0022-5347(05)67707-5","journal-title":"J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi M","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, et al.. Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014, 65:69-76. 10.1016\/j.eururo.2013.07.021","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"P\u00e9rez-Jacoiste As\u00edn MA","year":"2014","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, et al.. Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014, 93:236-54. 10.1097\/MD.0000000000000119","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206969-disseminated-mycobacterium-bovis-infection-a-rare-complication-of-bacillus-calmette-gurin-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:05Z","timestamp":1707509405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206969-disseminated-mycobacterium-bovis-infection-a-rare-complication-of-bacillus-calmette-gurin-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.50407","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}